H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Springworks Therapeutics (NASDAQ:SWTX) Inc on Thursday, setting a price target of $58, which is approximately 30.78% above the present share price of $44.35.
Burns expects Springworks Therapeutics Inc to post earnings per share (EPS) of -$0.37 for the third quarter of 2020.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Springworks Therapeutics, with an average price target of $58.
The analysts price targets range from a high of $58 to a low of $58.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$16.13 million. The company's market cap is $1.8 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 18.2% and a 58.62% success rate.
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.